Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. increased its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 25.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,551,802 shares of the company's stock after buying an additional 316,128 shares during the quarter. Vanguard Group Inc. owned about 4.69% of Tarsus Pharmaceuticals worth $27,576,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of TARS. Dimensional Fund Advisors LP increased its holdings in Tarsus Pharmaceuticals by 221.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 28,855 shares of the company's stock worth $485,000 after buying an additional 19,865 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Tarsus Pharmaceuticals by 3.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 48,583 shares of the company's stock worth $818,000 after buying an additional 1,402 shares during the period. UBS Group AG increased its holdings in Tarsus Pharmaceuticals by 37.0% in the 1st quarter. UBS Group AG now owns 4,226 shares of the company's stock worth $71,000 after buying an additional 1,142 shares during the period. Invesco Ltd. increased its holdings in Tarsus Pharmaceuticals by 17.1% in the 1st quarter. Invesco Ltd. now owns 27,982 shares of the company's stock worth $471,000 after buying an additional 4,078 shares during the period. Finally, State Street Corp increased its holdings in Tarsus Pharmaceuticals by 2.4% in the 1st quarter. State Street Corp now owns 132,883 shares of the company's stock worth $2,235,000 after buying an additional 3,141 shares during the period. Institutional investors and hedge funds own 90.01% of the company's stock.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 10,415 shares of the firm's stock in a transaction on Monday, March 18th. The stock was sold at an average price of $30.60, for a total value of $318,699.00. Following the transaction, the chief executive officer now owns 26,456 shares in the company, valued at approximately $809,553.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Tarsus Pharmaceuticals news, insider Aziz Mottiwala sold 4,766 shares of the firm's stock in a transaction on Monday, March 18th. The stock was sold at an average price of $30.60, for a total value of $145,839.60. Following the completion of the sale, the insider now directly owns 54,075 shares of the company's stock, valued at approximately $1,654,695. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bobak R. Azamian sold 10,415 shares of the firm's stock in a transaction on Monday, March 18th. The stock was sold at an average price of $30.60, for a total value of $318,699.00. Following the completion of the sale, the chief executive officer now directly owns 26,456 shares of the company's stock, valued at $809,553.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,496 shares of company stock worth $749,578. Corporate insiders own 11.54% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TARS. Jefferies Financial Group increased their price target on shares of Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the stock a "buy" rating in a report on Wednesday, March 6th. HC Wainwright raised their price objective on shares of Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the stock a "buy" rating in a research note on Wednesday, February 28th. Oppenheimer reaffirmed an "outperform" rating and set a $59.00 price objective (up previously from $55.00) on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 28th. Lifesci Capital reaffirmed an "outperform" rating on shares of Tarsus Pharmaceuticals in a research note on Tuesday, December 26th. Finally, Barclays raised their price objective on shares of Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Tarsus Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $48.38.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS traded down $2.12 during midday trading on Friday, reaching $36.17. 392,011 shares of the company's stock traded hands, compared to its average volume of 579,172. Tarsus Pharmaceuticals, Inc. has a 1 year low of $11.33 and a 1 year high of $40.40. The company has a market cap of $1.24 billion, a P/E ratio of -7.80 and a beta of 1.05. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.93. The company has a fifty day simple moving average of $33.44 and a two-hundred day simple moving average of $23.78.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its earnings results on Tuesday, February 27th. The company reported ($1.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.37) by $0.06. The business had revenue of $13.08 million for the quarter, compared to analysts' expectations of $4.63 million. During the same quarter last year, the business earned ($0.49) EPS. Equities analysts predict that Tarsus Pharmaceuticals, Inc. will post -4.59 EPS for the current fiscal year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.